1.605
price up icon5.92%   0.085
 
loading
Schlusskurs vom Vortag:
$1.52
Offen:
$1.55
24-Stunden-Volumen:
1.15M
Relative Volume:
0.68
Marktkapitalisierung:
$211.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.68M
KGV:
-0.9669
EPS:
-1.66
Netto-Cashflow:
$-54.24M
1W Leistung:
-9.04%
1M Leistung:
-13.90%
6M Leistung:
-29.07%
1J Leistung:
-79.39%
1-Tages-Spanne:
Value
$1.51
$1.615
1-Wochen-Bereich:
Value
$1.51
$1.82
52-Wochen-Spanne:
Value
$0.9857
$8.77

Cabaletta Bio Inc Stock (CABA) Company Profile

Name
Firmenname
Cabaletta Bio Inc
Name
Telefon
(267) 759-3100
Name
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Name
Mitarbeiter
163
Name
Twitter
@CabalettaBio
Name
Nächster Verdiensttermin
2025-03-31
Name
Neueste SEC-Einreichungen
Name
CABA's Discussions on Twitter

Vergleichen Sie CABA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CABA
Cabaletta Bio Inc
1.605 211.37M 0 -67.68M -54.24M -1.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.53 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
546.98 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.49 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
555.21 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.90 28.51B 3.81B -644.79M -669.77M -6.24

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-20 Herabstufung Evercore ISI Outperform → In-line
2024-12-19 Herabstufung Wells Fargo Overweight → Equal Weight
2024-10-10 Eingeleitet UBS Buy
2024-02-05 Eingeleitet Jefferies Buy
2023-11-29 Eingeleitet William Blair Outperform
2023-10-24 Eingeleitet Cantor Fitzgerald Overweight
2023-10-19 Eingeleitet Stifel Buy
2023-09-05 Eingeleitet Citigroup Buy
2023-07-18 Eingeleitet Guggenheim Buy
2023-01-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2022-08-30 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-12-08 Eingeleitet Wells Fargo Overweight
2021-10-19 Fortgesetzt Morgan Stanley Overweight
2021-06-30 Eingeleitet Mizuho Buy
2021-01-08 Eingeleitet Chardan Capital Markets Buy
2020-10-13 Eingeleitet H.C. Wainwright Buy
2019-11-19 Eingeleitet Cowen Outperform
2019-11-19 Eingeleitet Evercore ISI Outperform
2019-11-19 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten

pulisher
Jun 17, 2025

Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) PT at $20.33 - MarketBeat

Jun 17, 2025
pulisher
Jun 16, 2025

Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces market skepticism - Investing.com Australia

Jun 16, 2025
pulisher
Jun 16, 2025

Cabaletta Bio’s SWOT analysis: CAR-T pioneer’s stock faces market skepticism - Investing.com Australia

Jun 16, 2025
pulisher
Jun 16, 2025

Cabaletta Bio’s SWOT analysis: CAR-T pioneer’s stock faces market skepticism By Investing.com - Investing.com South Africa

Jun 16, 2025
pulisher
Jun 14, 2025

Cantor Fitzgerald Weighs in on Cabaletta Bio FY2026 Earnings - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Cabaletta Bio stock price target reiterated on strong clinical data By Investing.com - Investing.com India

Jun 13, 2025
pulisher
Jun 13, 2025

Cabaletta Bio stock price target reiterated on strong clinical data - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Cabaletta Bio Prices Public Offering to Raise $100 Million - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Cabaletta Bio Announces Public Offering of Common Stock and Warrants - MSN

Jun 12, 2025
pulisher
Jun 12, 2025

H.C. Wainwright reiterates buy rating on Cabaletta Bio stock By Investing.com - Investing.com Nigeria

Jun 12, 2025
pulisher
Jun 12, 2025

H.C. Wainwright reiterates buy rating on Cabaletta Bio stock - Investing.com Australia

Jun 12, 2025
pulisher
Jun 12, 2025

Cabaletta Bio’s (CABA) Buy Rating Reaffirmed at HC Wainwright - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Analysts Offer Predictions for Cabaletta Bio FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Cabaletta Bio Launches Public Offering Of Stock And Warrants - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio (CABA) Shares Drop 20% After Public Offering Annou - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio (CABA) Showcases Promising Rese-cel Data at EULAR 2025 | CABA Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio announces public offering of common stock and warrants By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio prices $100 million public offering of shares and warrants By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta reports positive clinical data for autoimmune cell therapy By Investing.com - Investing.com South Africa

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio looks to raise $100M in stock sale to fund cell therapy development - The Business Journals

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio (CABA) Receives Reiterated Buy Rating from HC Wain - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio (CABA) Receives Reiterated Buy Rating from HC Wainwright & Co. | CABA Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio shares CAR-T results in three autoimmune conditions - Endpoints News

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio Prices Securities Offering; Shares Fall - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio stock tumbles after pricing $100 million public offering By Investing.com - Investing.com Nigeria

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio stock tumbles after pricing $100 million public offering - Investing.com Australia

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio Announces Pricing of Public Offering of Securities - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio prices $100 million public offering of shares and warrants - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio: Sector Headwinds And Funding Issues, But Also Some Clear Clinical Direction - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio announces public offering of common stock and warrants - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio (CABA) Launches Public Offering with Warrants | CABA Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio Announces Proposed Public Offering of Securities | - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio Announces Proposed Public Offering of Securities - The Manila Times

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio Announces Proposed Public Offering of Securities | CABA Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress | CABA Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - The Manila Times

Jun 11, 2025
pulisher
Jun 11, 2025

Cabaletta reports positive clinical data for autoimmune cell therapy - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Breakthrough: New Autoimmune Therapy Achieves Drug-Free Remission in 94% of Trial Patients - Stock Titan

Jun 11, 2025
pulisher
Jun 10, 2025

Cabaletta Bio Stockholders Approve Key Proposals - TipRanks

Jun 10, 2025

Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.05
price up icon 1.77%
$35.85
price down icon 0.53%
$21.32
price down icon 0.15%
$99.46
price down icon 1.19%
$108.80
price up icon 2.21%
biotechnology ONC
$246.51
price up icon 1.76%
Kapitalisierung:     |  Volumen (24h):